Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2004.12.918
Annals of Surgical Oncology 11:203S-207 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coventry, B. J.
Right arrow Articles by Gill, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coventry, B. J.
Right arrow Articles by Gill, P. G.

SUPPLEMENT

Sentinel Lymph Node Dissection and Lymphatic Mapping for Local Subcutaneous Recurrence in Melanoma Treatment: Longer-Term Follow-Up Results

Brendon J. Coventry, BMBS, PhD, FRACS, Barry Chatterton, MBBS, FRACP, DDU, Fergus Whitehead, MBBS, FRCPA, Craig James, MBBS (Hons), FRCPA and P. Grantley Gill, MBBS, MD, FRACS

From the Adelaide Melanoma Unit and Breast Endocrine and Surgical Oncology Unit, Department of Surgery (BJC, PGG), University of Adelaide, and Department of Nuclear Medicine (BC), Royal Adelaide Hospital, North Terrace; and Department of Pathology (FW, CJ), Institute of Medical and Veterinary Sciences, and Adelaide Pathology Partners, West Terrace, Adelaide, South Australia.

Correspondence: Address correspondence and reprint requests to: Brendon J. Coventry, BMBS, PhD, FRACS, Adelaide Melanoma Unit, Department of Surgery, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia; Fax: 61-2-8222-5896; E-mail: bcoventry{at}medicine.adelaide.edu.au

ABSTRACT

Lymphatic mapping and sentinel lymph node dissection (LM/SLND) for surgical staging of cutaneous primary melanoma is currently being evaluated, but the role of these techniques in recurrent (secondary) melanoma is largely unexplored. Our experience with 12 patients indicates the potential usefulness of LM/SLND in the management of locally recurrent melanoma at subcutaneous sites. We have even used mapping to localize the sentinel node draining a subcutaneous local recurrence after previous LM/SLND for primary melanoma. The application of LM/SLND may therefore be extended beyond primary melanoma management as we understand more about the technical issues and appropriate selection of patients.

Key Words: Lymphatic mapping • Secondary • Sentinel node biopsy • Subcutaneous melanoma recurrence






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.